N
NEUROCRINE BIOSCIENCES INC
NASDAQ: NBIX (Neurocrine Biosciences, Inc.)
Last update: 3 hours ago123.10
-14.34 (-10.43%)
| Previous Close | 137.44 |
| Open | 132.34 |
| Volume | 4,166,691 |
| Avg. Volume (3M) | 1,032,436 |
| Market Cap | 12,354,742,272 |
| Price / Earnings (TTM) | 32.91 |
| Price / Earnings (Forward) | 19.76 |
| Price / Sales | 5.38 |
| Price / Book | 4.69 |
| 52 Weeks Range | |
| Earnings Date | 4 May 2026 |
| Profit Margin | 12.68% |
| Operating Margin (TTM) | 4.14% |
| Diluted EPS (TTM) | 2.95 |
| Quarterly Revenue Growth (YOY) | 11.10% |
| Quarterly Earnings Growth (YOY) | -81.80% |
| Total Debt/Equity (MRQ) | 19.45% |
| Current Ratio (MRQ) | 3.13 |
| Operating Cash Flow (TTM) | 529.90 M |
| Levered Free Cash Flow (TTM) | 235.48 M |
| Return on Assets (TTM) | 8.75% |
| Return on Equity (TTM) | 12.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Neurocrine Biosciences, Inc. | Bearish | Bullish |
AIStockmoo Score
-0.5
| Analyst Consensus | 1.0 |
| Insider Activity | -1.5 |
| Price Volatility | 1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Core |
| % Held by Insiders | 1.06% |
| % Held by Institutions | 98.86% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Dodge & Cox | 30 Sep 2025 | 5,556,618 |
| Aqr Capital Management Llc | 30 Sep 2025 | 2,773,648 |
| Bellevue Group Ag | 30 Sep 2025 | 1,763,105 |
| Los Angeles Capital Management Llc | 31 Dec 2025 | 1,291,278 |
| Deerfield Management Company, L.P. | 30 Sep 2025 | 1,184,345 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 200.00 (TD Cowen, 62.47%) | Buy |
| Median | 178.00 (44.60%) | |
| Low | 169.00 (Truist Securities, 37.29%) | Buy |
| Average | 182.22 (48.03%) | |
| Total | 7 Buy, 2 Hold | |
| Avg. Price @ Call | 144.41 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 23 Jan 2026 | 178.00 (44.60%) | Buy | 136.18 |
| JP Morgan | 12 Jan 2026 | 177.00 (43.79%) | Buy | 132.66 |
| Morgan Stanley | 08 Jan 2026 | 175.00 (42.16%) | Hold | 135.57 |
| Truist Securities | 08 Jan 2026 | 169.00 (37.29%) | Buy | 135.57 |
| HC Wainwright & Co. | 17 Dec 2025 | 198.00 (60.84%) | Buy | 141.70 |
| Mizuho | 12 Dec 2025 | 175.00 (42.16%) | Hold | 152.80 |
| Stifel | 11 Dec 2025 | 188.00 (52.72%) | Buy | 154.75 |
| RBC Capital | 08 Dec 2025 | 180.00 (46.22%) | Buy | 154.99 |
| TD Cowen | 05 Dec 2025 | 200.00 (62.47%) | Buy | 155.51 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ABERNETHY MATT | - | 136.06 | -1,368 | -186,130 |
| BENEVICH ERIC | - | 136.06 | -1,292 | -175,790 |
| BOYER DAVID W. | - | 136.06 | -1,189 | -161,775 |
| COOKE JULIE | - | 136.06 | -997 | -135,652 |
| DELAET INGRID | - | 136.06 | -475 | -64,629 |
| GANO KYLE | - | 136.06 | -1,580 | -214,975 |
| GORMAN KEVIN CHARLES | - | 136.06 | -2,845 | -387,091 |
| LIPPOLDT DARIN | - | 136.06 | -1,335 | -181,640 |
| ONYIA JUDE | - | 136.06 | -142 | -19,321 |
| Aggregate Net Quantity | -11,223 | |||
| Aggregate Net Value ($) | -1,527,001 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 136.06 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ONYIA JUDE | Officer | 31 Jan 2026 | Disposed (-) | 142 | 136.06 | 19,321 |
| ONYIA JUDE | Officer | 31 Jan 2026 | Option execute | 238 | - | - |
| LIPPOLDT DARIN | Officer | 31 Jan 2026 | Disposed (-) | 1,335 | 136.06 | 181,640 |
| LIPPOLDT DARIN | Officer | 31 Jan 2026 | Option execute | 2,373 | - | - |
| GORMAN KEVIN CHARLES | Director | 31 Jan 2026 | Disposed (-) | 2,845 | 136.06 | 387,091 |
| GORMAN KEVIN CHARLES | Director | 31 Jan 2026 | Option execute | 5,142 | - | - |
| GANO KYLE | Officer | 31 Jan 2026 | Disposed (-) | 1,580 | 136.06 | 214,975 |
| GANO KYLE | Officer | 31 Jan 2026 | Option execute | 2,927 | - | - |
| DELAET INGRID | Officer | 31 Jan 2026 | Disposed (-) | 475 | 136.06 | 64,629 |
| DELAET INGRID | Officer | 31 Jan 2026 | Option execute | 801 | - | - |
| COOKE JULIE | Officer | 31 Jan 2026 | Disposed (-) | 997 | 136.06 | 135,652 |
| COOKE JULIE | Officer | 31 Jan 2026 | Option execute | 1,741 | - | - |
| ABERNETHY MATT | Officer | 31 Jan 2026 | Disposed (-) | 1,368 | 136.06 | 186,130 |
| ABERNETHY MATT | Officer | 31 Jan 2026 | Option execute | 2,437 | - | - |
| BENEVICH ERIC | Officer | 31 Jan 2026 | Disposed (-) | 1,292 | 136.06 | 175,790 |
| BENEVICH ERIC | Officer | 31 Jan 2026 | Option execute | 2,294 | - | - |
| BOYER DAVID W. | Officer | 31 Jan 2026 | Disposed (-) | 1,189 | 136.06 | 161,775 |
| BOYER DAVID W. | Officer | 31 Jan 2026 | Option execute | 2,096 | - | - |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |